Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
2023-05-09 Purchase | 2023-05-11 9:16 pm | ACELYRIN Inc. | SLRN | Westlake BioPartners Fund II L.P. Westlake BioPartners GP II LLC Harper Sean E 10% Owner | 1,250,000 | $18 | $22,500,000 | 9,790,729 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
2024-02-12 Conversion | 2024-02-14 5:35 pm | N/A N/A | Kyverna Therapeutics Inc. | KYTX | Westlake BioPartners Fund I L.P. Westlake BioPartners GP I LLC Westlake BioPartners Opportunity Fund I L.P. Westlake BioPartners Opportunity GP I LLC Harper Sean E 10% Owner | 25,112,758 | $0 | 735,984 (Indirect) | View |
Ownership | 2024-02-07 9:51 pm | N/A N/A | Kyverna Therapeutics Inc. | KYTX | Westlake BioPartners Fund I L.P. Westlake BioPartners GP I LLC Westlake BioPartners Opportunity Fund I L.P. Westlake BioPartners Opportunity GP I LLC Harper Sean E 10% Owner | 0 | $0 | 4,523,924 (Indirect) | View |
2023-05-09 Conversion | 2023-05-11 9:16 pm | N/A N/A | ACELYRIN Inc. | SLRN | Westlake BioPartners Fund II L.P. Westlake BioPartners GP II LLC Harper Sean E 10% Owner | 17,081,458 | $0 | 9,790,729 (Direct) | View |
Ownership | 2023-05-04 7:10 pm | N/A N/A | ACELYRIN Inc. | SLRN | Westlake BioPartners Fund II L.P. Westlake BioPartners GP II LLC Harper Sean E 10% Owner | 0 | $0 | 8,540,729 (Direct) | View |